Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features

The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, S. aureus isolates with complete resistance to vancomycin have emerged in recent years. Vancom...

Descripción completa

Detalles Bibliográficos
Autores principales: Cong, Yanguang, Yang, Sijin, Rao, Xiancai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015472/
https://www.ncbi.nlm.nih.gov/pubmed/32071785
http://dx.doi.org/10.1016/j.jare.2019.10.005
Descripción
Sumario:The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, S. aureus isolates with complete resistance to vancomycin have emerged in recent years. Vancomycin-resistant S. aureus (VRSA) is mediated by a vanA gene cluster, which is transferred from vancomycin-resistant enterococcus. Since the first VRSA isolate was recovered from Michigan, USA in 2002, 52 VRSA strains have been isolated worldwide. In this paper, we review the latest progresses in VRSA, highlighting its resistance mechanism, characteristics of VRSA infections, as well as clinical treatments.

Ejemplares similares